Table 3

Multivariable Cox regression analysis of overall survival

Discovery cohort
(n=53)
Confirmation cohort
(n=126)
Validation cohort
(n=158)
HR (95% CI)P valueHR (95% CI)P valueHR (95% CI)P value
MGR
 ≤3.9 mm/month111
 >3.9 mm/month9.1 (3.2 to 25.4)<0.00013.8 (2.1 to 6.7)<0.00012.9 (1.6 to 5.3)0.00036
Diameter of largest TL
 ≤Median111
 >Median0.3 (0.1 to 0.9)0.0221.3 (0.6 to 3.0)0.470.7 (0.3 to 1.5)0.34
Sum of RECIST TLs
 ≤Median111
 >Median3.1 (1.0 to 9.6)0.0460.6 (0.3 to 1.3)0.161.3 (0.6 to 2.7)0.45
Liver metastasis
 No111
 Yes2.4 (0.9 to 6.5)0.0812.0 (1.1 to 3.4)0.0162.0 (1.2 to 3.3)0.0088
CNS metastasis
 No111
 Yes2.9 (1.1 to 8.2)0.0392.2 (1.3 to 3.8)0.00581.3 (0.7 to 2.4)0.40
LDH
 ≤ULN111
 >ULN1.6 (0.7 to 3.8)0.281.7 (0.9 to 3.1)0.0811.5 (0.9 to 2.5)0.16
Line of treatment
 First line111
 Second line0.8 (0.3 to 2.4)0.730.7 (0.4 to 1.3)0.282.0 (1.1 to 3.9)0.033
 ≥Third line0.9 (0.2 to 3.1)0.841.0 (0.5 to 1.9)0.962.3 (1.2 to 4.3)0.012
  • CNS, central nervous system; LDH, lactate dehydrogenase; MGR, metastatic growth rate; RECIST, response evaluation criteria in solid tumors version 1; ULN, upper limit of normal.